多囊卵巢综合征患者子宫内膜不典型增生的药物转化分析

Drug Transformation Analysis of Endometrial Atypical Hyperplasia in Patients with Polycystic Ovary Syndrome(PCOS)

目的：分析多囊卵巢综合征（PCOS）患者子宫内膜不典型增生的药物转化疗效及安全性。方法：回顾性分析17例PCOS子宫内膜不典型增生患者，其中9例曾用孕激素治疗未转化者为A组；8例未曾治疗者为B组，均检测口服葡萄糖耐量试验（OGTT）并同时行胰岛素释放试验，以检测患者是否存在胰岛素抵抗（IR）及高胰岛素血症。17例患者均采用口服避孕药联合二甲双胍治疗。结果：17例PCOS患者均存在IR及高胰岛素血症，经药物治疗3-6个周期后，内膜不典型病变均成功转化。结论：采用口服避孕药联合二甲双胍治疗PCOS合并承的子宫内膜不典型增生患者是一种临床上实用、有效的治疗方法。

Objective： To analyze the efficacy and safety of drugs on reverse of atypical endometrial hyperplasia in patients with polycystic ovary syndrome （PCOS）. Methods： A retrospective analysis on 17 patients with PCOS complicated by atypical endometrial hyperplasia was performed （9 patients who were treated with progestin but not reversed were considered as group A; 8 patients who were untreated were considered as group B）. Both groups received OGTT and insulin release test, to check whether the patients had insulin resis- tance （IR） or hyperinsulinemia. The 17 patients were treated with oral contraceptives combined with metformin. Results： After the 17 patients with PCOS complicated by IR and hyperinsulinemia received drug treatment for 3-6 cycles, atypical endometrial ＇hyperplasia was successfully reversed. Conclusion： Oral contraceptives combined with metformin is a clinically practical and effective method for treatment of PCOS complicated by atypical IR endometrial hyperplasia.